Breaking News

PRA Acquires ClinStar

March 4, 2013

Expands ops in Russia and Eastern Europe

PRA has acquired ClinStar, LLC, a privately held CRO managing Phase I-IV trials in the Russia, Ukraine, Belarus and the Baltic States. The acquisition supports PRA's growth efforts in Russia and Eastern Europe.
 
The acquisition also includes ClinStar's stand-alone clinical trial warehousing and logistics division, IMP Logistics, operating in Russia, Ukraine and Belarus, which offers cold chain logistics services that include importation of investigational products, clinical supplies, laboratory kits and printed materials, storage in multiple temperature zones, distribution to sites, collection of returned medication and coordination of product destruction. PRA plans to integrate ClinStar and IMP Logistics’ 300 employees. Financial terms were not disclosed.
 
"With ClinStar's high-caliber staff, culture and passion for customer service, it is a logical fit for PRA," said Colin Shannon, president and chief executive officer, PRA. "ClinStar will augment PRA's operations and expertise in Russia and Eastern Europe. Their knowledge and experience in this region complements PRA's overall global reach and infrastructure. We look forward to welcoming ClinStar employees into PRA and combining the expertise of both organizations to benefit both PRA's and ClinStar's clients."
 
"Our fast patient enrollment, unsurpassed quality and over a decade of successful study delivery in a highly desired geographic location has helped ClinStar to become one of the most well recognized geographically-focused CROs in Eastern Europe," said David Passov, president and chief executive officer of ClinStar, who now serves as senior vice president of Eastern Europe with PRA.

Related Packaging:

Related Compliance:

  • CROs and Today’s  R&D Landscape

    CROs and Today’s R&D Landscape

    Kristin Brooks, Associate Editor, Contract Pharma||November 9, 2016
    John Lewis of ACRO discusses opportunities, challenges, and the future CRO

  • Choosing Oral Formulations for First-in-man Clinical Trials

    Choosing Oral Formulations for First-in-man Clinical Trials

    Jon Sutch, Senior Manager of Formulation Development, Patheon||October 11, 2016
    Early formulations should be simple, but selecting a simple formulation isn’t as easy as it seems

  • Robust Assay Designs

    Robust Assay Designs

    Tim Wright, Editor, Contract Pharma||October 11, 2016
    Easing the transition from preclinical to clinical research